Canadian Centre for Vaccinology

What Canadian Centre for Vaccinology does

The Canadian Centre for Vaccinology (CCfV) is a privately-operated academic vaccine research centre headquartered in Halifax, Nova Scotia, established in 2007 as a tripartite collaboration of Dalhousie University, IWK Health, and Nova Scotia Health. CCfV operates as an integrated end-to-end vaccine research platform spanning preclinical discovery, Controlled Human Infection Models (CHIMs), Phase I–IV clinical trials, and post-market surveillance. Its research is organized into three groups — Vaccine Discovery (basic sciences and target identification), Vaccine Evaluation (clinical trials including first-in-human Phase 1 studies), and Policy, Programs, and Implementation (bioethics, health law, and social sciences) — supported by four core service lines: Clinical Trial Services, CL2 Laboratory Services, Data Management and Analysis, and the Challenge Unit, a specialized ten-bed negative-pressure HEPA-filtered inpatient facility for human challenge studies that is one of only a handful of its kind worldwide and the first in Canada to host an inpatient challenge trial (whooping cough, 2022).

CCfV's business model is a hybrid of competitive research grants (from agencies such as CIHR, PHAC, and the Canada Foundation for Innovation), industry-sponsored clinical trial contracts (with sponsors including Pfizer, GSK, Sanofi Pasteur, and Aromis Biotechnologies), and tiered facility access fees. Pricing operates on a three-tiered structure: at-cost budgets for Canadian academic, government, and NGO users, and cost-plus margins for industry and for-profit users, with an Operations Committee reviewing all user requests for feasibility, scientific merit, financial viability, and risk. Access is managed through a centralized business development function led by a Senior Manager. Upcoming capacity additions include GMP BioLabs East in 2027, adding GMP biomanufacturing and additional CL2 labs. Revenue is not publicly disclosed.

The customer base spans pharmaceutical and biotechnology companies conducting contract trials, federal and provincial health agencies funding surveillance and policy research, academic collaborators across Canada, global health organizations, and research participants. Notable engagements include the Pfizer BEATRIX Phase III maternal GBS vaccine trial and a GSK $1M capacity-building grant (May 2023). In 2024 CCfV was selected to lead the Canadian Biomanufacturing Cooperative sub-network of the Canadian Pandemic Preparedness Hub (CP2H), positioning it within Canada's national pandemic preparedness infrastructure. Ownership is institutional via the three founding partners, with no disclosed private equity or venture capital.

Name

Canadian Centre for Vaccinology

Legal name

Canadian Center for Vaccinology

Website

https://centerforvaccinology.ca

Company type

Private

Founded year

1992

Operating status

Operating

Headcount range

11–50 employees

Short description

Canadian Centre for Vaccinology is an academic vaccine research centre in Halifax operating as a collaboration of Dalhousie University, IWK Health, and Nova Scotia Health, providing end-to-end Phase I–IV clinical trials, CL2 laboratory services, and Canada-leading Controlled Human Infection Model studies for pharmaceutical, biotech, government, and academic clients.

Ownership category

akta.pro rank

Headquarters

HQ city

Halifax

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Infrastructure, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Competitive Research Grants: CCfV's work is partially funded through competitive academic, government, and industry research grants from agencies such as Canada Foundation for Innovation, Public Health Agency of Canada, Canadian Institutes for Health Research, and others.
2. Contract Clinical Trials: CCfV conducts clinical trials of novel vaccines on a contractual basis for manufacturers who provide funding to support these trials. Pricing follows a three-tiered process with at-cost budgets for academic/publicly funded users and cost-plus margin for industry/for-profit groups.
3. Facility and Service Access Fees: CCfV provides access to facilities and services to academic, industry, government, and global health partners. Pricing is based on user type: preferential pricing for Canadian academic, government, and NGO users; cost-plus margin for industry users.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

The Canadian Centre for Vaccinology (CCfV) is an interdisciplinary vaccine research centre that delivers end-to-end vaccine research services from preclinical discovery through Phase I-IV clinical trials and post-market evaluations. Core offerings include clinical trial management services, CL2 laboratory services, data management and analysis, and a specialized Challenge Unit for Controlled Human Infection Models (CHIMs), organized around three research groups covering vaccine discovery, vaccine evaluation, and policy/program implementation.

Product overview

The Canadian Center for Vaccinology (CCfV) is a multidisciplinary research center offering an integrated portfolio of vaccine research services and facilities. The organization operates as a collaboration of Dalhousie University, IWK Health, and Nova Scotia Health, providing end-to-end capabilities spanning preclinical studies, Controlled Human Infection Models (CHIMs), Phase I-IV clinical trials, and real-world effectiveness studies. Core offerings include Clinical Trial Services (Phase 1-4), Laboratory Services (CL2), Data Management and Analysis, and the specialized Challenge Unit for human infection studies. These services are organized around three research groups: the Vaccine Discovery Group (basic sciences and novel vaccine development), the Vaccine Evaluation Group (clinical trials and field studies), and the Policy, Programs, and Implementation (PPI) Group (bioethics, policy, and social sciences). The center also provides Clinical and Health Research Management Services for comprehensive project support.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Trial Services Comprehensive Phase 1-4 clinical trial management services covering recruitment, staffing, equipment management, pharmacy support, and monitoring. Services include eDiary management, illness surveillance, and dedicated clinical spaces with exam rooms and temperature-controlled storage, serving vaccine developers, academic researchers, and public health partners.
• Laboratory Services CL2 laboratory services for clinical trials, industry referral work, and collaborative infectious disease and immunology research. Capabilities include sample processing (serum, plasma, whole blood, RNA, saliva, urine, nasal swabs) and advanced assays including Pseudovirion Neutralization Assays, HAIs, ELISAs, ELISpot, PCR, cell cultures, bacteria culture, CMI testing, PRNT, CHO cell assays, viral propagation, and AST.
• Data Management and Analysis Data management and analysis service providing electronic case report form (eCRF) design, database creation and management, quality control, MedDRA and WHODrug coding, statistical analyses, and CDISC programming and data submission packages. Supports compliance with regulations and Good Clinical Data Management Practices (GCDMP), delivered through partnership with Alimentiv.
• Challenge Unit Specialized research facility featuring ten single-bed isolation rooms with negative air pressure and HEPA-filtered exhaust for conducting Controlled Human Infection Models (CHIMs), vaccine challenge studies, and other research requiring controlled environments. Located at IWK Health Centre in Halifax, the only facility of its kind in the Atlantic provinces and one of only a handful worldwide.
• Clinical and Health Research Management Services End-to-end project management services including protocol development, regulatory and ethical compliance, participant recruitment, study start-up and close-out procedures, and secure document storage. Supports vaccine-related research and infectious disease research including epidemiology, surveillance, and immunology studies.
• Vaccine Discovery Group Research Services Research services advancing basic sciences in vaccinology and immunology, focused on identifying and characterizing novel vaccine targets and evaluating platform technologies, formulations, and adjuvants in in vitro and in vivo animal models. Expertise spans bacteriology, molecular biology, virology, and immunology.
• Vaccine Evaluation Group Research Services Research services conducting clinical vaccine trials from first-in-human Phase 1 studies to post-licensure Phase 4 trials, including Clinical Human Infection Model (CHIM) trials and field effectiveness studies. Specializes in early phase clinical trials with over 25 first-in-human Phase 1 vaccine trials conducted.
• Policy, Programs, and Implementation (PPI) Group Research Services Research services providing cross-cutting expertise in health law, bioethics, policy development, and social sciences. Assesses public impact of new vaccines and technologies, evaluates vaccine acceptability, and addresses governance and commercial aspects of vaccine research.

Quantifiable outcome

• Conducted hundreds of clinical trials and studies across multiple phases
• +3 more outcomes

Named customers2 records

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Seven partnerships are on record, tiered core, major and supporting.

• Dalhousie UniversitycoreStrategic or Co-development PartnerCCfV is a collaboration of Dalhousie University, IWK Health, and Nova Scotia Health. Dalhousie provides academic leadership, research faculty, and institutional support. CCfV serves as a Dalhousie research centre adhering to the university's Research Centres and Institutes Policy.
• IWK HealthcoreStrategic or Co-development PartnerCCfV is a collaboration of Dalhousie University, IWK Health, and Nova Scotia Health. IWK Health provides clinical facilities including the main research facilities and Challenge Unit location, clinical staff, and healthcare infrastructure.
• Nova Scotia HealthcoreStrategic or Co-development PartnerCCfV is a collaboration of Dalhousie University, IWK Health, and Nova Scotia Health. Nova Scotia Health provides healthcare system integration and public health expertise, with representation on CCfV's Governing Council.
• PfizermajorStrategic or Co-development PartnerPfizer is conducting the BEATRIX Phase III Maternal GBS clinical trial through CCfV, researching an investigational maternal vaccine designed to protect pregnant women and their babies from Group B Streptococcus.
• Aromis Biotechnologies IncmajorStrategic or Co-development PartnerAromis Biotechnologies Inc partnered with CCfV for a clinical trial evaluating a plant-based seasonal influenza vaccine. The experimental vaccine uses virus-like particles produced by plant cells.
• Canadian Pandemic Preparedness Hub (CP2H)majorStrategic or Co-development PartnerIn 2024, CCfV received funding from CBRF-BRIF to participate in CP2H and lead the Canadian Biomanufacturing Cooperative sub-network, contributing to pandemic preparedness efforts.
• AlimentivsupportingTechnology or IntegrationAlimentiv provides CDISC programming and data submission package services for CCfV's Data Management and Analysis team, supporting regulatory-compliant clinical data processing.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• IQVIA: IQVIA is the largest global CRO and competes with CCfV for industry-sponsored vaccine trials. As a broad incumbent, it offers wider scale and geographic reach but lacks CCfV's specialized CHIM/Challenge Unit capability.
• Worldwide Clinical Trials: Worldwide Clinical Trials is a mid-sized global CRO providing Phase I–IV clinical research services, including vaccine trials. As a broad incumbent, it competes for the same commercial vaccine sponsors CCfV targets but operates at larger scale without CHIM specialization.
• ICON plc: ICON is a large global CRO providing Phase I–IV clinical trial services across therapeutic areas including vaccines. It is a broader incumbent competing for the same commercial vaccine trial contracts but without CCfV's academic affiliation or CHIM specialization.

Direct peers

• Canadian Immunization Research Network (CIRN): CIRN is a national network of Canadian vaccine researchers that CCfV actively participates in and is referenced on its own website. Comparable in scope of vaccine research coordination across Canadian academic institutions.
• Center for Vaccine Development and Global Health (University of Maryland): University of Maryland's CVD is a long-established academic vaccine research center conducting Phase I–IV trials and infectious disease research, comparable in mission and structure to CCfV as a university-affiliated vaccine research enterprise.
• Infectious Diseases Clinical Research Consortium (IDCRC): IDCRC is the NIH-funded network that succeeded the Vaccine and Treatment Evaluation Units (VTEUs), coordinating vaccine clinical trial execution across U.S. academic centers—comparable to how CCfV participates in Canadian networks like PCIRN and CIRN.
• hVIVO plc: hVIVO (formerly Retroscreen Virology) is a UK-based contract research organization specializing in Controlled Human Infection Model (CHIM) studies and human challenge trials. It is the closest direct peer to CCfV's Challenge Unit, competing for the same global human-challenge sponsors and operating a similar specialized isolation-room infrastructure.
• Vaccine and Infectious Disease Organization (VIDO, University of Saskatchewan): VIDO is Canada's largest vaccine research and development organization, operating CL2/CL3 facilities and GMP manufacturing capacity. It is the most direct Canadian peer to CCfV, comparable in academic affiliation, CL2/CL3 infrastructure, and end-to-end vaccine R&D scope.
• Vaccine Research Center (NIH/NIAID VRC): The NIH VRC is a major intramural vaccine research program conducting first-in-human clinical trials and translational vaccinology, directly comparable to CCfV's Vaccine Evaluation Group in early-phase and first-in-human trial capabilities.
• Baylor College of Medicine – Vaccine and Treatment Evaluation Unit (VTEU): Baylor's VTEU is part of the NIH-funded IDCRC network and conducts vaccine clinical trials across all phases, comparable to CCfV's role as a major academic vaccine trial site.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/ccfv-hfx

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Canadian Centre for Vaccinology